TAGAMET HB 200
LOE ApproachingNDAORALSUSPENSION
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET HB 200 is an oral suspension small-molecule formulation approved in 1999, indicated for gastrointestinal acid-related conditions. The drug's mechanism of action involves histamine H2-receptor antagonism to reduce gastric acid production. This product represents a mature, well-established therapeutic option in the OTC/consumer healthcare space.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling constrained team resources and focus on efficiency over expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAGAMET HB 200 offers limited career growth potential given its LOE-approaching status and minimal linked job openings. Roles available are primarily operational and maintenance-focused rather than strategic or growth-oriented.
Brand ManagerField Sales Representative
Worked on TAGAMET HB 200 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.